elamipretide (ophthalmic)
Dry Age-Related Macular Degeneration
Phase 3Active (MMPOWER-3 enrolling)
Key Facts
Indication
Dry Age-Related Macular Degeneration
Phase
Phase 3
Status
Active (MMPOWER-3 enrolling)
Company
About Stealth BioTherapeutics
Stealth BioTherapeutics is a biotechnology company pioneering mitochondria-targeted therapeutics, having achieved a landmark accelerated FDA approval for FORZINITY™ (elamipretide) injection for the ultra-rare Barth syndrome in September 2025. The company is advancing its lead compound in other indications, including dry age-related macular degeneration (AMD), a large market with no approved therapies. Founded in 2006 and headquartered in Newton, Massachusetts, Stealth operates as a public company, transitioning from a development-stage firm to one with its first commercial product.
View full company profileTherapeutic Areas
Other Dry Age-Related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Dry-AMD High-Throughput Model | Axol Bioscience | Research/Preclinical Tools |
| Lead Dry AMD Program | Perceive Biotherapeutics | Preclinical |
| Undisclosed PolyCol program | Stuart Therapeutics | Pre-clinical |